A clinical-stage biopharmaceutical company building an "off-the-shelf" class of immunotherapy - where the active ingredient is a living immune cell.
Above: the company wordmark. Founded 2018, spun out of Jerusalem's Hadassah-Hebrew University Medical Center; now headquartered in Tampa, Florida with manufacturing in Israel and trials across Southeast Asia.
Most of modern cell therapy runs on a slow, personal ritual. A patient's own immune cells are drawn, shipped to a lab, engineered, grown, and shipped back - a bespoke drug built one human at a time. Mirror Biologics is arguing for a different premise: that a potent immune-cell medicine should sit in a freezer, ready for anyone who needs it.
That is the idea behind AlloStim, the company's lead product candidate. It is an "off-the-shelf," non-genetically-manipulated, disease-agnostic living immune cell, derived from precursor cells purified from the blood of healthy donors and expanded in bioreactors designed to mimic an "artificial lymph node." Because it is allogeneic - made from donor material rather than the patient's own - it can be manufactured in advance and delivered like a conventional drug.
Underneath sits the Mirror Effect platform, protected by more than 200 issued patents worldwide. The platform's stated aim is deceptively simple: reverse-engineer the components of an immune cascade that are proven to work, while excluding the associated toxicities. In other words, keep the parts of the immune response that kill disease and leave behind the parts that harm the patient.
The technology has a specific origin. It was developed inside the Hadassah-Hebrew University Medical Center in Jerusalem before being spun out. Today the company is a Delaware corporation headquartered in Tampa, Florida, with GMP manufacturing in Jerusalem and clinical operations in Thailand and Malaysia - a distributed operation for a team of roughly sixteen people.
What makes the approach worth watching is its breadth. The same platform drug is being pointed at three very different problems: cancer, viral infection, and the slow decline of the immune system with age. That is a deliberate design choice. If the active ingredient is a living immune cell that can be taught to prime a broad response, then the disease it treats becomes almost a matter of context and combination.
None of this is approved yet. Mirror Biologics is pre-commercial, and its candidates are moving through mid- and late-stage trials. But the direction of travel is clear, and in early 2025 it earned a notable vote of confidence when Merck KGaA agreed to supply its checkpoint inhibitor for a Mirror-sponsored cancer study.
Mirror Biologics is pioneering a new class of immunotherapy in which the active ingredients are living immune cells.
A simplified view of the AlloStim manufacturing path. The goal is reproducibility - a living-cell product that can be made the same way, at scale, and shipped ready to use.
An off-the-shelf, disease-agnostic living immune cell in late-stage clinical development, including a Phase II/IIB program in metastatic colorectal cancer. Designed to be combined with checkpoint inhibitors to spark a broader anti-tumor response.
A universal anti-respiratory-viral approach that uses AlloStim cells to restore cellular immunity in the elderly - aiming to protect against COVID variants, influenza and RSV. Completed a Phase I/II trial in adults over 65.
An immunomodulatory neoantigen vaccine that combines heat-shock proteins released from tumor or virus-infected cells - lysed by activated immune cells - with AlloStim. The tumor effectively supplies its own antigen.
The engine behind every candidate: it reverse-engineers effective immune cascades while excluding their toxicities. Protected by more than 200 issued patents worldwide and built to be disease-agnostic.
The cell therapy field splits roughly into patient-specific (autologous) approaches like CAR-T and off-the-shelf (allogeneic) approaches. Mirror Biologics sits firmly on the allogeneic side, competing with players such as Allogene, Fate Therapeutics and Adicet. The relative bars below are an illustrative comparison of positioning, not a performance benchmark.
Illustrative positioning based on public company descriptions - not a measured clinical or commercial ranking.
These patients have limited treatment options and are refractory to existing therapies.
Established as a Delaware corporation to develop living immune-cell therapies spun out of Hadassah-Hebrew University Medical Center.
The off-the-shelf living immune cell candidate progresses across cancer and infectious-disease indications.
A Phase I/II trial begins testing AlloStim-based allo-priming to protect adults over 65 from respiratory viruses.
Mirror closes the final $20M tranche of its $30M Series A and appoints Elizabeth Czerepak as CFO and VP Corporate Development.
Partners with Merck KGaA on a colorectal cancer trial and publishes Phase I/II AlloPrime immunosenescence results.
Founder and Chief Medical Officer; architect of the Mirror Effect technology and the company's clinical strategy.
Joined April 2024 and served as acting CEO (July 2024-May 2025). A biotech finance veteran and former Managing Director at Bear Stearns and JPMorgan.
Hong Kong-based backer of the $30M Series A, with the final $20M tranche closing in April 2024.
Merck KGaA collaboration (2025) - clinical trial and avelumab supply agreement for a Phase II metastatic colorectal cancer study (NCT06557278).
AlloPrime results published (2025) - Phase I/II data suggesting allo-priming can reverse immunosenescence in adults over 65.
GMP facility cleared - Israel's Ministry of Health approved the design of a new Jerusalem manufacturing facility.
200+ issued patents - a broad intellectual-property moat around the Mirror Effect platform and products.
Direct video links were not confirmed from public sources; the buttons open curated YouTube searches.
It develops off-the-shelf immunotherapies whose active ingredients are living, non-genetically-manipulated immune cells - led by AlloStim, with AlloPrime and StimVax in the pipeline, all built on its patented Mirror Effect platform.
AlloStim is allogeneic and off-the-shelf, made from healthy-donor blood and not genetically engineered, so it can be manufactured in advance and delivered like a conventional drug rather than custom-built from each patient's own cells.
A 2025 clinical trial and supply agreement in which Mirror sponsors a Phase II study combining AlloStim with Merck KGaA's checkpoint inhibitor avelumab (BAVENCIO) in metastatic colorectal cancer.
It closed a $30M Series A led by Bradbury Asset Management (Hong Kong), with the final $20M tranche completed in April 2024; total reported funding is around $34M.
It is headquartered in Tampa, Florida, with GMP manufacturing in Jerusalem, Israel and clinical operations in Thailand and Malaysia.
Sources include mirrorbio.com, LinkedIn, BioSpace, GlobeNewswire, PR.com, JLM-BioCity, PubMed and Crunchbase. Figures such as funding totals and employee counts are approximate and drawn from public listings.